Transgenion

A spin-off from the Medical University of Vienna, Transgenion is a research and development firm focused on precision medicine for age-related Chronic Inflammatory Diseases (CIDs). The company was founded in 2015 by Prof. Dr. Rolf Ziesche, an expert in pulmonary medicine who was named Inventor of the Year by the Medical University of Vienna in 2016. Dr. Ziesche and his team have conducted over two decades of translational research, culminating in the establishment of Transgenion. The company's work, supported by significant national and EU funding, aims to bridge the gap between applied clinical sciences and the pharmaceutical industry.

Transgenion develops clinically validated biomarkers that serve as targets for precision medicine, with an initial focus on Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF). This approach allows for the early and predictive diagnosis of disease progression and enables the development of causal treatments. The company's business strategy involves creating diagnostic tests and identifying drug candidates, with a plan to advance the sale of licenses within 3 to 4 years. By combining medical and biomolecular research, Transgenion has built a strong intellectual property portfolio with 25 patents granted in the EU, US, and Japan.

The firm's primary product is a set of biomarkers intended to link diagnosis directly with targeted therapy, a method that has proven successful in oncology and which Transgenion is pioneering for CIDs. This strategy is designed to increase therapeutic effectiveness while reducing side effects. The company targets the significant market for CIDs, which the WHO considers a major threat to human health and which affects a large percentage of the population over 50. Keywords: precision medicine, chronic inflammatory diseases, COPD, biomarkers, pulmonary medicine, diagnostics, translational research, Idiopathic Pulmonary Fibrosis, regenerative medicine, biopharmaceutical